Yuhan Corp
000105
Company Profile
Business description
Yuhan Corp is a pharmaceutical company. The core business of the company is classified as primary and specialty care, dietary supplements, household and animal care, and contract manufacturing of active pharmaceutical ingredients. The company offers one-stop custom synthesis services from research and development to commercial production of active pharmaceutical products (APIs) and intermediates for the following disease treatments: antivirals (HCV and HIV), antibiotics, antihistamines, antidiabetics, beta-lactamase inhibitors, CNS intermediates, and PEGylated compounds for international markets.
Contact
74, Noryangjin-ro
Dongjak-gu
Seoul
KORT: +82 28280181
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,117
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,979.40 | 22.00 | -0.24% |
CAC 40 | 7,850.43 | 106.02 | 1.37% |
DAX 40 | 24,240.82 | 198.92 | 0.83% |
Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
FTSE 100 | 9,061.49 | 37.68 | 0.42% |
HKSE | 25,621.79 | 83.72 | 0.33% |
NASDAQ | 21,020.02 | 127.33 | 0.61% |
Nikkei 225 | 41,881.24 | 709.92 | 1.72% |
NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
S&P 500 | 6,358.91 | 49.29 | 0.78% |
S&P/ASX 200 | 8,709.60 | 27.60 | -0.32% |
SSE Composite Index | 3,593.84 | 11.54 | 0.32% |